• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    • News
      All News Research Reports
    • Reports

    P
    Pharmaceuticals & Biotech.
    SECTOR | 24 Aug 2023

    Q1FY24 result review : US glows, margin revival next

    buy
    Pharmaceuticals & Biotech.
    by ICICI Securities Limited
    ICICI Securities Limited
    Windfall from the ongoing drug shortages and traction in gRevlimid sales in the US drove 16% / 45% / 41% YoY increase in revenue / EBITDA / PAT in Q1FY24 for the pharma companies under our coverage. Gross and EBITDA margins rose 300bps / 440bps YoY to 65.3% / 23.8% on an aggregate basis.
    Copy Link Share on Share on Share on Share on
    Alert  
    More from Pharmaceuticals & Biotech.
    Recommended
    As IPO fever hits new high, Crizac and three other listings on the horizon
    | 07 Jul 2025, 05:34PM
    Market closes flat, Sharda Motor's board approves 1:1 bonus share allotment
    Trendlyne Marketwatch | 07 Jul 2025, 03:55PM
    Volume-led growth, price stabilization and new US launches boost Indian pharma
    | 25 Mar 2024
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd